---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122766"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:47:31.124997+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa reports Q3 net loss $23.9M; announces Novartis deal for VAV1 degraders with $150M upfront

## Summary
- Net loss of $23.9M for Q3 2024; collaboration revenue of $9.2M from Roche.
- Global license with Novartis for VAV1 MGDs: $150M upfront, up to $2.1B milestones, U.S. P&L share.
- MRT-6160 Phase 1 SAD/MAD ongoing; initial safety and PD data expected by Q1 2025.
- MRT-2359 Phase 1/2 in MYC-driven tumors; updated results and Phase 2 guidance by year-end 2024.
- Cash $247.1M at Sept 30; plus $150M Novartis upfront extends runway into 2028.

## SEC filing metadata
- accession: 0000950170-24-122766
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017024122766/0000950170-24-122766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017024122766/glue-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122766
- JSON: https://secwatch.observer/filing/0000950170-24-122766.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122766.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.